Sign In
Buy NCNA
$2.03
-0.0400 (-1.93%)
At Close: Jun 03, 2026
NuCana Appoints Ian Webster as Chief Financial Officer
08:00am, Monday, 01'st Jun 2026
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improvin
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 14'th May 2026
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 19'th Mar 2026
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
NuCana Appoints Theresa Bruce as Chief Operating Officer
08:00am, Tuesday, 06'th Jan 2026
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment ou
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
08:00am, Wednesday, 10'th Dec 2025
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Dur
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 13'th Nov 2025
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued List
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
08:00am, Wednesday, 05'th Nov 2025
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CN
NuCana Compliant with All Nasdaq Continued Listing Criteria
08:00am, Friday, 05'th Sep 2025
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Ma
NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
08:00am, Wednesday, 03'rd Sep 2025
EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medica
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 20'th Aug 2025
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
NuCana Announces ADS Ratio Change
04:05pm, Friday, 01'st Aug 2025
EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company's previously disclosed plans to
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
08:05am, Monday, 21'st Jul 2025
EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issue
NuCana Announces Plan to Implement ADS Ratio Change
10:30am, Friday, 11'th Jul 2025
EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADS
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 02'nd Jun 2025
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 20'th Mar 2025
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025
